In Vivo-Engineered T Cell Programs

About TScan Therapeutics

TScan Therapeutics is a fully integrated, clinical-stage biotech focused on unleashing the immune system through TCR-T cell therapies. Founded in 2018, the company's lead program, TSC-101, is in a Phase 1 trial for AML and MDS, and it has a pipeline of candidates for solid tumors and autoimmune disorders. TScan differentiates itself with a proprietary platform for target discovery and is advancing both ex vivo and in vivo engineered T cell approaches.

Therapeutic Areas